Curated News
By: NewsRamp Editorial Staff
April 24, 2026
Lantern Pharma to Demonstrate withZeta.ai AI Co-Scientist Platform Live
TLDR
- Lantern Pharma's withZeta.ai platform gives early adopters a competitive edge in accelerating oncology drug discovery and commercialization.
- The platform integrates clinical, molecular, and scientific datasets via multi-agentic AI to execute complex oncology research workflows in real time.
- Lantern Pharma aims to accelerate drug discovery for rare cancers, bringing hope to patients with unmet medical needs.
- Lantern Pharma will host its first live public demo of the withZeta.ai AI co-scientist platform on April 30, 2026.
Impact - Why it Matters
This news matters because Lantern Pharma’s withZeta.ai platform represents a leap forward in AI-driven oncology drug discovery. By integrating multi-agentic AI with clinical and molecular data, the platform aims to drastically shorten the timeline for developing treatments for rare cancers—an area often neglected due to high costs and low patient populations. For patients, this could mean faster access to life-saving therapies. For investors, the subscription-based model opens a new revenue stream, potentially boosting the company’s valuation. The live demonstration on April 30, 2026, offers a rare opportunity to see cutting-edge AI in action, validating the technology’s real-world applicability.
Summary
Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets. Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model.
Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For more information, visit www.AINewsWire.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma to Demonstrate withZeta.ai AI Co-Scientist Platform Live
